Product Reports Resources Pricing Login Book a demo

ArsenalBio

Biotech & Life Sciences · San Francisco, United States · Founded 2019

Arsenal Biosciences, Inc. is a clinical stage biotechnology startup that operates in the healthcare sector, specifically in the field of cancer treatment. The company's primary focus is on developing programmable cell therapies aimed at combating solid tumor cancers. In simpler terms, they are working on ways to reprogram cells to fight cancer more effectively. Their business model revolves around the research, development, and eventual commercialization of these innovative cell therapies. The company's target clients are primarily patients suffering from solid tumor cancers, a group that represents a significant portion of the global cancer patient population. Arsenal Biosciences generates revenue through the development and sale of these therapies. As a clinical stage company, much of their current work is focused on research and development, with the goal of bringing their therapies to market. Once their therapies are approved and commercialized, the company will generate income from the sale of these treatments to healthcare providers. The company's team is composed of experts from various scientific disciplines, as well as professionals with clinical and manufacturing experience. This diverse team is united by a common purpose: to defeat cancer through the development of innovative and effective treatments. Keywords: Biotechnology, Healthcare, Cancer Treatment, Solid Tumor, Programmable Cell Therapy, Research and Development, Clinical Stage, Commercialization, Innovative Treatments, Diverse Expertise.

Investors

23 investors on ArsenalBio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 16 investors entered at this stage
University of California, Santa Cruz
Euclidean Capital
Parker Institute for Cancer Immunotherapy
Osage Venture Partners
Kleiner Perkins
Westlake Village BioPartners
SoftBank Vision Fund
Bristol-Myers Squibb
Emerson Collective
Sixth Street Growth
Hitachi Ventures
UCSF Foundation Investment Company
SoftBank
Green Sands Equity
Waycross Ventures
Byers Capital
Series B+ 7 investors entered at this stage
Rock Springs Capital
Luma Group
Regeneron Ventures
ARCH Venture Partners
T. Rowe Price
Milky Way Investments
NVentures

Global footprint

Where ArsenalBio has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States99.4%
🇨🇭 Switzerland0.6%
2 countries shown

Talent graph

The shape of ArsenalBio's talent

Dealroom maps ArsenalBio's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

11 team members profilednamed & role-tagged by Dealroom
181 employeestotal headcount
3 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock ArsenalBio's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about ArsenalBio

An AI-synthesized read of the highest-engagement posts about ArsenalBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ArsenalBio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.